Last kr84.00 SEK
Change Today +0.50 / 0.60%
Volume 355.2K
SOBI On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
OTC US
OTC US
As of 11:29 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Open
kr83.50
Previous Close
kr83.50
Day High
kr84.00
Day Low
kr82.60
52 Week High
07/3/14 - kr94.75
52 Week Low
03/26/14 - kr65.00
Market Cap
23.1B
Average Volume 10 Days
518.7K
EPS TTM
kr-0.97
Shares Outstanding
270.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, is engaged in the development, manufacture, and sale of pharmaceuticals primarily in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its principal products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. The company also offers various products, including Defibrotide, Erwinase, Ferriprox, and Willfact for used in the haematology therapeutic area; Aloxi, Cometriq, Kepivance, Megace, Multiferon, Removab, and Yondelis for use in the oncology therapeutic area; Cyanokit, Fomepizole, Ruconest, and ViperaTAb for use as emergency medicines and antidotes; and Betapred, Buronil, Mezavant, and Xiapex for the treatment of infectious diseases and specialty care. In addition, it develops rFVIIIFc, which is under Phase III clinical trials for the treatment of hemophilia A; rFIXFc that is under Phase III clinical trials to treat hemophilia B; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002, a complement C5 inhibitor, which is in Phase I clinical trials to treat genetic and metabolic diseases. The company has an agreement with Pfizer for the manufacture of drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A; and Biogen Idec for the development and commercialization of recombinant factor VIII and factor IX hemophilia programs. It also has a collaboration agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

569 Employees
Last Reported Date: 10/30/14

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.3M
Compensation as of Fiscal Year 2013.

swedish orphan biovitrum ab (SOBI) Key Developments

Exelixis, Inc. and Swedish Orphan Biovitrum AB Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer

Exelixis, Inc. announced that it has extended and restructured its agreement with Swedish Orphan Biovitrum AB to support the distribution and commercialization of COMETRIQ® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The agreement, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019. Moreover, the payment structure of the partnership will transition from fixed fees paid by Exelixis to Sobi to support initial build out of COMETRIQ European commercial infrastructure to a sales margin-based approach. Exelixis continues to maintain commercial rights for all other potential cabozantinib oncology indications on a global basis. Sobi exclusively markets, sells, and distributes COMETRIQ for its MTC indication in the covered territory of the European Union, Switzerland, Norway, Russia, and Turkey. In parts of the territory where COMETRIQ is not approved, Sobi administers a Named Patient Use program. Exelixis is responsible for regulatory approvals in the covered territory, and the company retains the ability to terminate the agreement at will at any time upon payment of certain pre-determined fees.

Swedish Orphan Biovitrum AB Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 10:00 AM

Swedish Orphan Biovitrum AB Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 10:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Swedish Orphan Biovitrum AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fiscal 2014

Swedish Orphan Biovitrum AB announced earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported profit was SEK 52.7 million, or SEK 0.20 per share, compared to a loss of SEK 56.4 million, or SEK 0.21 loss per share, for the same quarter ended September 30, 2013. Total revenues for the third quarter ended September 30, 2014 were SEK 665.9 million, compared to SEK 517.3 million for the same quarter ended September 30, 2013. For the nine months ended September 30, 2014, loss was SEK 250.4 million, or SEK 0.94 loss per share, compared to a loss of SEK 79.5 million, or SEK 0.30 loss per share, for the same period ended September 30, 2013. Total revenues for the nine months ended September 30, 2014 were SEK 1.9 billion, compared to SEK 1.57 billion for the same period ended September 30, 2013. For 2014, the company expects total revenues to be in the range of SEK 2.3 billion to SEK 2.5 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr84.00 SEK +0.50

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.45 EUR -0.07
Oxford Biomedica PLC 7.00 GBp -0.15
Veloxis Pharmaceuticals A/S kr1.16 DKK -0.01
View Industry Companies
 

Industry Analysis

SOBI

Industry Average

Valuation SOBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit www.biovitrum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.